{{Rsnum
|rsid=2622604
|Gene=ABCG2
|Chromosome=4
|position=88157772
|Orientation=plus
|GMAF=0.1832
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABCG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 57.5 | 34.5 | 8.0
| HCB | 61.4 | 35.6 | 3.0
| JPT | 79.5 | 18.2 | 2.3
| YRI | 83.0 | 17.0 | 0.0
| ASW | 78.2 | 18.2 | 3.6
| CHB | 61.4 | 35.6 | 3.0
| CHD | 62.6 | 30.8 | 6.5
| GIH | 74.3 | 20.8 | 5.0
| LWK | 76.6 | 19.6 | 3.7
| MEX | 70.7 | 29.3 | 0.0
| MKK | 84.2 | 15.1 | 0.7
| TSI | 61.6 | 32.3 | 6.1
| HapMapRevision=28
}}{{PMID Auto
|PMID=19696792
|Title=Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression
}}

{{PharmGKB
|RSID=rs2622604
|Name_s=ABCG2 SNP in intron 1; rs2622604 C>T
|Gene_s=ABCG2
|Feature=Intron
|Evidence=PubMed ID:19696792
|Annotation=Risk or phenotype-associated allele: T. Phenotype: This SNP was associated with increased risk of myelosuppression in cancer patients treated with irinotecan. Study size: 108. Study population/ethnicity: Japanese patients with neoplasms; Japan. Significance metric(s): p = 0.036. Type of association: PK; CO.
|Drugs=irinotecan
|Drug Classes=
|Diseases=Anemia; Drug Toxicity; Leukopenia; Neoplasms; Neutropenia; Thrombocytopenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165292176
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2622604
|overall_frequency_n=100
|overall_frequency_d=128
|overall_frequency=0.78125
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=84
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}